IS SWITCHING FROM IV TO SC ABATACEPT THERAPY SUSTAINABLE IN THE REAL WORLD? 1-YEAR ANALYSIS OF THE PROSPECTIVE, INTERNATIONAL ACTION STUDY

被引：0
|
作者：
Alten, R. [1 ]
Nuesslein, H. [2 ]
Galeazzi, M. [3 ]
Lorenz, H. M. [4 ]
Mariette, X. [5 ]
Cantagrel, A. [6 ]
Chartier, M. [7 ]
Elbez, Y. [8 ]
Rauch, C. [9 ]
Le Bars, M. [10 ]
机构：
[1] Schlosspk Klin Univ Med, Berlin, Germany
[2] Univ Erlangen Nurnberg, Nurnberg, Germany
[3] Univ Siena, Siena, Italy
[4] Univ Hosp, Heidelberg, Germany
[5] Univ Paris Sud, Paris, France
[6] Hop Purpan, Toulouse, France
[7] Chiltern Int, Neuilly, France
[8] Excelya, Boulogne, France
[9] Bristol Myers Squibb, Munich, Germany
[10] Bristol Myers Squibb, Rueil Malmaison, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
SUBCUTANEOUS FORMULATION;
D O I：
10.1136/annrheumdis-2016-eular.1515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0371
引用
收藏
页码：1030 / 1031
页数：2
相关论文
共 50 条
  • [21] ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTING
    Allen, R.
    Rauch, C.
    Chartier, M.
    Nurmohamed, M. T.
    Connolly, S.
    Buch, M. H.
    Peichl, P.
    Mariette, X.
    Patel, Y.
    Marsal, S.
    Caporali, R.
    Griffiths, H.
    Sanmarti, R.
    Bannert, B.
    Elbez, Y.
    Lozenski, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 511 - 512
  • [22] Baseline characteristics and 1-year outcomes of patients with polypoidal choroidal vasculopathy: an interim analysis from the real-world LUMINOUS™ study
    Koh, Adrian H. C.
    Das Gupta, Ayan
    Margaron, Philippe
    Lacey, Sue
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [23] Predictors of 1-Year Clinical Outcomes in Real World Patients from XIENCE V® USA Study.
    Krucoff, Mitchell W.
    Hermiller, James
    Mao, Vivian
    Zhao, Weiying
    Wang, Jin
    Jonnavithula, Lalitha
    Fink, Stanley
    Sudhir, Krishnankutty
    Rutledge, David
    CIRCULATION, 2010, 122 (21)
  • [24] Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study
    Calabrese, Laura
    Cinotti, Elisa
    D'onghia, Martina
    Cartocci, Alessandra
    Rubegni, Pietro
    Maccari, Francois
    Boulard, Claire
    Reguiai, Ziad
    Becherel, Pierre Andre
    Jacobzone, Caroline
    Begon, Edouard
    Fite, Charlotte
    Walls, Beatrice
    Liegeon, Anne Laure
    Parier, Josiane
    Chaby, Guillaume
    Perrot, Jean-Luc
    ACTA DERMATO-VENEREOLOGICA, 2025, 105
  • [25] Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study
    Lurz, Philipp
    Rommel, Karl-Philipp
    Schmitz, Thomas
    Bekeredjian, Raffi
    Nickenig, Georg
    Moellmann, Helge
    von Bardeleben, Ralph Stephan
    Schmeisser, Alexander
    Atmowihardjo, Iskandar
    Estevez-Loureiro, Rodrigo
    Lubos, Edith
    Heitkemper, Megan
    Peterman, Kelli
    Lapp, Harald
    Donal, Erwan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (07) : 607 - 616
  • [26] The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study
    Trojano, M.
    Van Pesch, V.
    Al Roughani, R.
    Rovira, A.
    Cutter, G.
    Dzhenkova, D.
    Hagenbuch, N.
    Kantaria, R.
    Craveiro, L.
    Hobart, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 635 - 635
  • [27] THE DUTCH 1-YEAR RESOURCE USE RESULTS FROM THE EXPERIENCE STUDY, AN INTERNATIONAL REGISTRY OF REAL-WORLD OUTCOMES FOR ASTHMA PATIENTS TREATED WITH OMALIZUMAB
    van Nooten, F.
    Thompson, C.
    Brown, R.
    Groot, M.
    VALUE IN HEALTH, 2011, 14 (07) : A496 - A496
  • [28] PREDICTORS OF RETENTION WITH ABATACEPT IN PATIENTS WHO HAVE FAILED ONE OR MORE BIOLOGIC AGENTS: RESULTS FROM THE INTERNATIONAL, REAL-WORLD ACTION STUDY
    Nuesslein, Hubert
    Alten, Rieke
    Galeazzi, Maurizio
    Lorenz, Hannes M.
    Nurmohamed, Michael T.
    Bensen, William
    Burmester, Gerd R.
    Peter, Hans-Hartmut
    Pavelka, Karel
    Chartier, Melanie
    Poncet, Coralie
    Rauch, Christiane
    Le Bars, Manuela
    RHEUMATOLOGY, 2014, 53 : 94 - 95
  • [29] Predictors of retention with abatacept in patients who have failed one or more biologic agents: results from the international, real-world ACTION study
    Nuesslein, H.
    Alten, R.
    Galeazzi, M.
    Lorenz, H.
    Boumpas, D.
    Nurmohamed, M.
    Bensen, W.
    Burmester, G.
    Peter, H.
    Rainer, F.
    Pavelka, K.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    LeBars, M.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 108 - 108
  • [30] PREDICTORS OF RETENTION WITH ABATACEPT IN PATIENTS WHO HAVE FAILED ONE OR MORE BIOLOGIC AGENTS: RESULTS FROM THE INTERNATIONAL, REAL-WORLD ACTION STUDY
    Nuesslein, H.
    Alten, R.
    Galeazzi, M.
    Lorenz, H. M.
    Boumpas, D.
    Nurmohamed, M. T.
    Bensen, W. G.
    Burmester, G. R.
    Peter, H. -H.
    Rainer, F.
    Pavelka, K.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    Le Bars, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 616 - 616
12345